The timing hypothesis and hormone replacement therapy: A paradigm shift in the primary prevention of coronary heart disease in women. Part 1: Comparison of therapeutic efficacy

Journal of the American Geriatrics Society

Volumn 61, Issue 6, 2013, Pages 1005-1010

  Hodis, Howard N ^a   Mack, Wendy J ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

hormone therapy in women; meta analyses; statins; timing hypothesis; women and CHD prevention

Indexed keywords

ACETYLSALICYLIC ACID; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ADULT; AGED; ARTICLE; CARDIOVASCULAR RISK; DRUG EFFICACY; FEMALE; HORMONE SUBSTITUTION; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MORTALITY; POSTMENOPAUSE; PRIMARY PREVENTION;

CORONARY DISEASE; ESTROGEN REPLACEMENT THERAPY; FEMALE; HUMANS; MENOPAUSE; PRIMARY PREVENTION; TIME FACTORS; TREATMENT OUTCOME;

EID: 84879146880     PISSN: 00028614     EISSN: 15325415     Source Type: Journal    
DOI: 10.1111/jgs.12140     Document Type: Article

References (27)

1. Walsh JME, Pignone M,. Drug treatment of hyperlipidemia in women. JAMA 2004; 291: 2243-2252.
2. Petretta M, Costanzo P, Perrone-Filardi P, et al. Impact of gender in primary prevention of coronary heart disease with stain therapy: A meta-analysis. Int J Cardiol 2010; 138: 25-31.
3. Mizuno K, Nakaya N, Ohashi Y, et al. Usefulness of pravastatin in primary prevention of cardiovascular events in women: Analysis of the Management of Elevated Cholesterol in the Primary Prevention Group of Adult Japanese (MEGA Study). Circulation 2008; 117: 494-502.
4. Brugts JJ, Yetgin T, Hoeks SE, et al. The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: Meta-analysis of randomised controlled trials. BMJ 2009; 338: b2376.
5. Mora S, Glynn RJ, Hsia J, et al. Statins for the primary prevention of cardiovascular events in women with elevated high-sensitivity c-reactive protein or dyslipidemia: Results from the Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) and meta-analysis of women from primary prevention trials. Circulation 2010; 121: 1069-1077.
6. de Lorgeril M, Salen P, Abramson J, et al. Cholesterol lowering, cardiovascular diseases, and rosuvastatin-JUPITER controversy. Arch Intern Med 2010; 170: 1032-1036.
7. Kaul S, Morrissey RP, Diamond GA,. By Jove! What is a clinician to make of JUPITER? Arch Intern Med 2010; 170: 1073-1077.
8. Berger JS, Roncaglioni MC, Avanzini F, et al. Aspirin for the primary prevention of cardiovascular events in women and men: A sex-specific meta-analysis of randomized controlled trials. JAMA 2006; 295: 306-313.
9. Ridker PM, Cook NR, Lee IM, et al. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med 2005; 352: 1293-1304.
10. Ogawa H, Nakayama M, Morimoto T, et al. Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: A randomized controlled trial. JAMA 2008; 300: 2134-2141.
11. Wing LMH, Reid CM, Ryan P, et al. A comparison of outcomes with angiotensin-converting-enzyme inhibitors and diuretics for hypertension in the elderly. N Engl J Med 2003; 348: 583-592.
12. Shekelle PG, Rich MW, Morton SC, et al. Efficacy of angiotensin- converting enzyme inhibitors and beta-blockers in the management of left ventricular systolic dysfunction according to race, gender, and diabetic status: A meta-analysis of major clinical trials. J Am Coll Cardiol 2003; 41: 1529-1538.
13. Hodis HN, Mack WJ,. A window of opportunity: The reduction of coronary heart disease and total mortality with menopausal therapies is age and time dependent. Brain Res 2011; 1379: 244-252.
14. Salpeter SR, Walsh JME, Greyber E, et al. Coronary heart disease events associated with hormone therapy in younger and older women: A meta-analysis. J Gen Intern Med 2006; 21: 363-366.
15. Grodstein F, Stampfer M,. The epidemiology of coronary heart disease and estrogen replacement in postmenopausal women. Prog Cardiol Dis 1995; 38: 199-210.
16. Grodstein F, Stampfer M,. Estrogen for women at varying risk of coronary disease. Maturitas 1998; 30: 19-26.
17. Rossouw JE, Prentice RL, Manson JE, et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA 2007; 297: 1465-1477.
18. LaCroix AZ, Chlebowski RT, Manson JE, et al. Health outcomes after stopping conjugated equine estrogens among postmenopausal women with hysterectomy: A randomized controlled trial. JAMA 2011; 305: 1305-1314.
19. Schierbeck LL, Rejnmark L, Tofteng CL, et al. Effect of hormone replacement treatment on cardiovascular events in recently postmenopausal women: Randomized trial. BMJ 2012; 345: e6409.
20. Salpeter SR, Walsh JME, Greyber E, et al. Mortality associated with hormone replacement therapy in younger and older women: A meta-analysis. J Gen Intern Med 2004; 19: 791-804.
21. Salpeter SR, Cheng J, Thabane L, et al. Bayesian meta-analysis of hormone therapy and mortality in younger postmenopausal women. Am J Med 2009; 12: 1016-1022.
22. Salpeter SR, Buckley NS, Liu H, et al. The cost-effectiveness of hormone therapy in younger and older postmenopausal women. Am J Med 2009; 122: 42-52.
23. Cohen DJ, Reynolds MR,. Interpreting the results of cost-effectiveness studies. J Am Coll Cardiol 2008; 52: 2119-2126.
24. Shepherd J, Blauw GJ, Murphy MB, et al. Pravastatin in Elderly Individuals at Risk of Vascular Disease (PROSPER): A randomized controlled trial. Lancet 2002; 360: 1623-1630.
25. US Food and Drug Administration. FDA drug safety communication: Important safety label changes to cholesterol lowering statin drugs [on-line]. Available at http://www.fda.gov/drugs/drugsafety/ucm293101.htm Accessed October 10, 2012.
26. Redberg RF, Katz MH,. Healthy men should not take statins. JAMA 2012; 307: 1491-1492.
27. Utian WH,. A decade post WHI, menopausal hormone therapy comes full circle-need for independent commission. Climacteric 2012; 15: 320-325.